BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15626722)

  • 1. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase.
    Ennis BW; Fultz KE; Smith KA; Westwick JK; Zhu D; Boluro-Ajayi M; Bilter GK; Stein B
    J Pharmacol Exp Ther; 2005 Apr; 313(1):325-32. PubMed ID: 15626722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.
    Gross ND; Boyle JO; Du B; Kekatpure VD; Lantowski A; Thaler HT; Weksler BB; Subbaramaiah K; Dannenberg AJ
    Clin Cancer Res; 2007 Oct; 13(19):5910-7. PubMed ID: 17908987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest.
    Kuntzen C; Sonuc N; De Toni EN; Opelz C; Mucha SR; Gerbes AL; Eichhorst ST
    Cancer Res; 2005 Aug; 65(15):6780-8. PubMed ID: 16061660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of endoreduplication by a JNK inhibitor SP600125 in human lung carcinoma A 549 cells.
    Miyamoto-Yamasaki Y; Yamasaki M; Tachibana H; Yamada K
    Cell Biol Int; 2007 Dec; 31(12):1501-6. PubMed ID: 17904874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A c-Jun NH2-terminal kinase inhibitor SP600125 (anthra[1,9-cd]pyrazole-6 (2H)-one) blocks activation of pancreatic stellate cells.
    Masamune A; Kikuta K; Suzuki N; Satoh M; Satoh K; Shimosegawa T
    J Pharmacol Exp Ther; 2004 Aug; 310(2):520-7. PubMed ID: 15056726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125.
    Wang B; Tsukada J; Higashi T; Mizobe T; Matsuura A; Mouri F; Sawamukai N; Ra C; Tanaka Y
    Genes Cells; 2006 Sep; 11(9):983-92. PubMed ID: 16923120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of ozone-induced airway inflammation and hyper-responsiveness by c-Jun NH2 terminal kinase inhibitor SP600125.
    Williams AS; Issa R; Leung SY; Nath P; Ferguson GD; Bennett BL; Adcock IM; Chung KF
    J Pharmacol Exp Ther; 2007 Jul; 322(1):351-9. PubMed ID: 17460151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase.
    Sun ZJ; Chen G; Zhang W; Hu X; Huang CF; Wang YF; Jia J; Zhao YF
    J Pharmacol Exp Ther; 2010 Aug; 334(2):500-12. PubMed ID: 20484154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of c-Jun N-terminal kinase sensitizes tumor cells to flavonoid-induced apoptosis through down-regulation of JunD.
    Kook SH; Son YO; Jang YS; Lee KY; Lee SA; Kim BS; Lee HJ; Lee JC
    Toxicol Appl Pharmacol; 2008 Mar; 227(3):468-76. PubMed ID: 18078968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest.
    Li JY; Huang JY; Xing B; Ren KW; Li M; Wei D; Gu PY; Chen G; Gu B; Zhang GF; Hu WX
    Pharmazie; 2012 Nov; 67(11):942-6. PubMed ID: 23210245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JNK as a positive regulator of angiogenic potential in endothelial cells.
    Uchida C; Gee E; Ispanovic E; Haas TL
    Cell Biol Int; 2008 Jul; 32(7):769-76. PubMed ID: 18455449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of radiosensitivity by inhibition of c-Jun N-terminal kinase activity in a Lewis lung carcinoma‑bearing subcutaneous tumor mouse model.
    Li CH; Lim SH; Ryu HH; Moon KS; Jung TY; Jung S
    Oncol Rep; 2016 Dec; 36(6):3397-3404. PubMed ID: 27779695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conflicting evidence for the role of JNK as a target in breast cancer cell proliferation: Comparisons between pharmacological inhibition and selective shRNA knockdown approaches.
    Wood RA; Barbour MJ; Gould GW; Cunningham MR; Plevin RJ
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.
    Okada M; Shibuya K; Sato A; Seino S; Watanabe E; Suzuki S; Seino M; Kitanaka C
    Oncol Rep; 2013 Oct; 30(4):1957-64. PubMed ID: 23912840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.
    Hideshima T; Hayashi T; Chauhan D; Akiyama M; Richardson P; Anderson K
    Oncogene; 2003 Nov; 22(54):8797-801. PubMed ID: 14647474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of c-Jun N-terminal kinase in G2/M arrest and FasL-mediated apoptosis induced by a novel indoloquinoline derivative, IQDMA, in K562 cells.
    Yang SH; Chien CM; Lu CM; Chen YL; Chang LS; Lin SR
    Leuk Res; 2007 Oct; 31(10):1413-20. PubMed ID: 17397922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of rapamycin in LS174T colon cancer cells.
    Benoit M; Dormond-Meuwly A; Demartines N; Dormond O
    J Surg Res; 2011 May; 167(2):e193-8. PubMed ID: 21324487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo.
    Hsu YL; Cho CY; Kuo PL; Huang YT; Lin CC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):484-94. PubMed ID: 16632641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.